MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock

Rhea-AI Summary

MAIA (NYSE American: MAIA) priced an underwritten public offering of 20,000,000 common shares at $1.50 per share for aggregate gross proceeds of $30.0 million, with a 45-day option to sell up to an additional 3,000,000 shares. The offering is expected to close on March 4, 2026, subject to customary closing conditions.

MAIA intends to use net proceeds to fund clinical trials and for working capital and general corporate purposes; the offering was led by healthcare-dedicated investors and existing shareholders.

Positive

• $30.0 million aggregate gross proceeds expected
• Offering led by healthcare-dedicated investors and existing shareholders
• Proceeds earmarked for clinical trials and working capital
• Underwriters granted 45-day option for up to 3,000,000 additional shares

Negative

• Issuance of 20,000,000 shares may cause shareholder dilution
• Offering contains no warrant coverage, limiting investor sweeteners

Market Reaction – MAIA

-26.09% $1.53

15m delay 1 alert

-26.09% Since News

$1.53 Last Price

$1.52 $2.20 Day Range

-$27M Valuation Impact

$77M Market Cap

2K Volume

Following this news, MAIA has declined 26.09%, reflecting a significant negative market reaction. The stock is currently trading at $1.53. This price movement has removed approximately $27M from the company's valuation.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Shares offered: 20,000,000 shares Offering price: $1.50 per share Gross proceeds: $30 million +5 more

8 metrics

Shares offered 20,000,000 shares Underwritten public offering of common stock

Offering price $1.50 per share Public offering price for new common shares

Gross proceeds $30 million Aggregate gross proceeds before discounts and expenses

Over-allotment option 3,000,000 shares 45-day option for underwriters to buy additional common shares

Over-allotment period 45 days Duration of underwriters’ option to purchase extra shares

Expected closing date March 4, 2026 Anticipated closing of the public offering

Current price $2.07 Price prior to offering press release

Price move 24h -8.41% Change in share price before news publication

Market Reality Check

Price: $2.07 Vol: Volume 538,914 is below t...

normal vol

$2.07 Last Close

Volume Volume 538,914 is below the 20-day average of 651,120, suggesting no outsized trading ahead of this offering announcement. normal

Technical Shares at $2.07 are trading above the 200-day MA of $1.63, but sit 35.11% below the 52-week high and above the 52-week low.

Peers on Argus

MAIA was down 8.41% with 2 Argus-tracked peers (e.g., ARTV, JUNS) also moving do...

1 Up 2 Down

MAIA was down 8.41% with 2 Argus-tracked peers (e.g., ARTV, JUNS) also moving down (sector scanner notes a median move of about -3.7%), while 1 peer moved up, indicating both company-specific dilution and broader biotech pressure.

Historical Context

5 past events · Latest: Feb 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Clinical progress	Positive	+12.0%	Highlighted Phase 3 ateganosine momentum and large NSCLC market opportunity.
Jan 20	Corporate update	Positive	+26.4%	Outlined 2026 clinical milestones and prior-year progress for ateganosine.
Dec 24	Insider financing	Positive	+8.8%	Independent directors participated in a private placement alongside Phase 3 launch.
Dec 16	Private placement	Negative	-6.5%	Announced $1.51M private placement of shares and warrants to fund trials.
Dec 11	Clinical trial	Positive	+18.8%	Initiation of pivotal Phase 3 trial for ateganosine in advanced NSCLC.

Pattern Detected

Positive clinical and corporate updates have historically seen aligned positive price reactions, while financings like private placements have coincided with downside moves.

Recent Company History

Over the last six months, MAIA has reported multiple positive clinical milestones for ateganosine, including a pivotal Phase 3 initiation on Dec 11, 2025 and subsequent Phase 3 momentum updates, each followed by double‑digit percentage gains. Corporate updates outlining 2026 milestones and a private placement with director participation also moved the stock, with financings showing at least one negative reaction. Today’s common stock offering fits this pattern of recurring capital raises alongside advancing late‑stage oncology trials.

Market Pulse Summary

The stock is dropping -26.1% following this news. A negative reaction to this offering would be cons...

Analysis

The stock is dropping -26.1% following this news. A negative reaction to this offering would be consistent with MAIA’s history, where a prior private placement on Dec 16, 2025 aligned with a -6.5% move. The announcement adds 20,000,000 new shares at $1.50 and a 3,000,000-share over‑allotment option, increasing potential dilution. While proceeds support clinical trials and operations, repeated equity raises can weigh on sentiment and valuations if not matched by clear value‑creating milestones.

Key Terms

underwritten public offering, common stock, over-allotments, book-running manager, +2 more

6 terms

underwritten public offering financial

"today announced the pricing of its underwritten public offering of 20,000,000 shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

common stock financial

"20,000,000 shares of its common stock at a public offering price"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

over-allotments financial

"option to purchase up to an additional 3,000,000 shares of common stock ... to cover over-allotments"

An over-allotment is a temporary extra batch of shares that the underwriters of a stock offering are allowed to sell beyond the original amount, with the right to buy those shares back later. Think of it as spare tickets sold to meet demand and then reclaimed if needed to keep the market orderly; it helps stabilize the stock price after an offering and can affect short-term supply and potential dilution, which matters to investors tracking price and ownership stakes.

book-running manager financial

"is acting as the sole book-running manager for the offering"

A book-running manager is the lead organizer responsible for coordinating a large financial sale, such as issuing new stocks or bonds. They oversee preparing all necessary documents, setting the sale’s price, and finding buyers, much like a concert promoter arranging a major event. Their role matters to investors because they help ensure the offering is successfully sold at the best possible terms.

prospectus supplement regulatory

"The offering is being made only by means of a prospectus supplement and accompanying prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

registration statement regulatory

"that form a part of the registration statement.. A prospectus supplement describing"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. Not financial advice.

Financing included participation by healthcare-dedicated investors alongside
existing shareholders

CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.50 per share for aggregate gross proceeds of $30 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The offering is expected to close on March 4, 2026, subject to satisfaction of customary closing conditions.

The offering was structured as a straightforward common stock only investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders.

Konik Capital Partners, LLC, a division of T.R. Winston & Company is acting as the sole book-running manager for the offering.

MAIA intends to use the net proceeds from the offering to conduct clinical trials and for working capital and general corporate purposes.

The securities described above are being offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-273984), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 15, 2023, and declared effective on August 23, 2023.

The offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement.. A prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to this offering have been filed with the SEC.

Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting Konik Capital Partners LLC, a division of T.R. Winston & Company, at 7 World Trade Center, 46th Floor, New York, NY 10007, Attention: Capital Markets Team, Email: capmarkets@konikcapitalpartners.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MAIA Biotechnology

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com. 

Cautionary Note Regarding Forward-Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended). Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and (viii) the closing of our underwritten public offering of common stock, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. A detailed discussion of these uncertainties and risks that affect our business is contained in our SEC filings, including our reports on Form 10-K and Form 10-Q, particularly under the heading “Risk Factors.” Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

FAQ

What did MAIA announce about the March 3, 2026 public offering (MAIA)?

MAIA priced an underwritten offering of 20,000,000 shares at $1.50 for gross proceeds of $30.0 million. According to the company, there is a 45-day option to sell up to an additional 3,000,000 shares.

When is the MAIA (MAIA) offering expected to close and what conditions apply?

The offering is expected to close on March 4, 2026, subject to customary closing conditions. According to the company, closing depends on satisfaction of standard underwriter and regulatory requirements.

How does MAIA plan to use the net proceeds from the March 2026 offering (MAIA)?

MAIA intends to use net proceeds to conduct clinical trials and for working capital and general corporate purposes. According to the company, funding is targeted to support ongoing development activities.

Who led the MAIA underwritten public offering and what investor interest was noted?

The offering was led by Konik Capital Partners and included participation from healthcare-dedicated investors and existing shareholders. According to the company, that mix provided sector-specific investor support.

What is the total potential share count offered in MAIA's March 2026 deal (MAIA)?

The base offering is 20,000,000 shares with a 45-day over-allotment option for up to 3,000,000 additional shares. According to the company, the option covers potential over-allotments.

Does MAIA's March 2026 offering include warrants or other equity incentives (MAIA)?

No, the offering was structured as a straightforward common stock sale with no warrant coverage. According to the company, investors purchased common shares only, without attached warrants.